W. Kimryn Rathmell, Ph.D., M.D.

Professor

kimryn.rathmell@vanderbilt.edu

Visit Lab Site


Faculty Appointments
Professor of Medicine Professor of BiochemistryProfessor of Cancer BiologyCornelius Abernathy Craig Chair
Education
M.D., Stanford University, Stanford, CaliforniaPh.D., Biophysics, Stanford University, Stanford, CaliforniaB.S., Biology, University of Northern Iowa, Cedar Falls, IowaB.A., Chemistry, University of Northern Iowa, Cedar Falls, Iowa
Office Address
2220 Pierce Avenue
Preston Research Building, Suite 777
Nashville, TN 37232
Research Description
As the Director of the Division of Hematology and Oncology, I am invested in creating a basic, translational, and clinical program that supports each of our cancer programs.

As a genitourinary oncologist, I focus on renal cell carcinoma. Our laboratory is focused on cancers caused by deregulation of the normal hypoxia response pathway. We use clear cell renal cell carcinoma as a model system because virtually all of these tumors display dysregulation of this pathway. This cancer affects over 60,000 new patients annually in the US. Recent molecular discoveries based on understanding the hypoxia response pathway have led to the development of multiple new lines of treatment for this cancer. Our goal is to identify strategies to improve the treatment of cancers dependent on hypoxia pathway activation, or better ways to detect these cancers earlier. Therefore, our research takes a broad approach using genetic techniques to study tumor-initiating events and events that promote the development of invasive or metastatic features using in vitro, animal, and human systems. This translational research, all geared toward enhancing our understanding of the genetics and molecular biology of hypoxia-driven cancers, is folded into a clinical research program at the Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center.
Research Keywords
Renal cell carcinoma
Clinical Research Keywords
Kidney Cancer
Publications
Sun M, Tong P, Kong W, Dong B, Huang Y, Park IY, Zhou L, Liu XD, Ding Z, Zhang X, Bai S, German P, Powell R, Wang Q, Tong X, Tannir NM, Matin SF, Rathmell WK, Fuller GN, McCutcheon IE, Walker CL, Wang J, Jonasch E. HNF1B Loss Exacerbates the Development of Chromophobe Renal Cell Carcinomas. Cancer Res [print-electronic]. 2017 Oct 10/1/2017; 77(19): 5313-26. PMID: 28807937, PMCID: PMC5626626, PII: 0008-5472.CAN-17-0986, DOI: 10.1158/0008-5472.CAN-17-0986, ISSN: 1538-7445.

Chang EH, Chong WK, Kasoji SK, Fielding JR, Altun E, Mullin LB, Kim JI, Fine JP, Dayton PA, Rathmell WK. Diagnostic accuracy of contrast-enhanced ultrasound for characterization of kidney lesions in patients with and without chronic kidney disease. BMC Nephrol. 2017 Aug 8/9/2017; 18(1): 266. PMID: 28793871, PMCID: PMC5551034, PII: 10.1186/s12882-017-0681-8, DOI: 10.1186/s12882-017-0681-8, ISSN: 1471-2369.

Beckermann KE, Sharma D, Chaturvedi S, Msaouel P, Abboud MR, Allory Y, Bourdeaut F, Calderaro J, de Cubas AA, Derebail VK, Hong AL, Naik RP, Malouf GG, Mullen EA, Reuter VE, Roberts CWM, Walker CL, Wood CG, DeBaun MR, Van Poppel H, Tannir NM, Rathmell WK. Renal Medullary Carcinoma: Establishing Standards in Practice. J Oncol Pract. 2017 Jul; 13(7): 414-21. PMID: 28697319, PMCID: PMC5508447, DOI: 10.1200/JOP.2017.020909, ISSN: 1935-469X.

Siska PJ, Beckermann KE, Mason FM, Andrejeva G, Greenplate AR, Sendor AB, Chiang YJ, Corona AL, Gemta LF, Vincent BG, Wang RC, Kim B, Hong J, Chen CL, Bullock TN, Irish JM, Rathmell WK, Rathmell JC. Mitochondrial dysregulation and glycolytic insufficiency functionally impair CD8 T cells infiltrating human renal cell carcinoma. JCI Insight [print-electronic]. 2017 Jun 6/15/2017; 2(12): PMID: 28614802, PMCID: PMC5470888, PII: 93411, DOI: 10.1172/jci.insight.93411, ISSN: 2379-3708.

Yin Q, Hung SC, Wang L, Lin W, Fielding JR, Rathmell WK, Khandani AH, Woods ME, Milowsky MI, Brooks SA, Wallen EM, Shen D. Associations between Tumor Vascularity, Vascular Endothelial Growth Factor Expression and PET/MRI Radiomic Signatures in Primary Clear-Cell-Renal-Cell-Carcinoma: Proof-of-Concept Study. Sci Rep. 2017 Mar 3/3/2017; 7: 43356. PMID: 28256615, PMCID: PMC5335708, PII: srep43356, DOI: 10.1038/srep43356, ISSN: 2045-2322.

Siska PJ, Beckermann KE, Rathmell WK, Haake SM. Strategies to overcome therapeutic resistance in renal cell carcinoma. Urol. Oncol [print-electronic]. 2017 Mar; 35(3): 102-10. PMID: 28089416, PMCID: PMC5318278, PII: S1078-1439(16)30409-4, DOI: 10.1016/j.urolonc.2016.12.002, ISSN: 1873-2496.

Kasoji SK, Chang EH, Mullin LB, Chong WK, Rathmell WK, Dayton PA. A Pilot Clinical Study in Characterization of Malignant Renal-cell Carcinoma Subtype with Contrast-enhanced Ultrasound. Ultrason Imaging [print-electronic]. 2017 Mar; 39(2): 126-36. PMID: 27659687, PII: 0161734616666383, DOI: 10.1177/0161734616666383, ISSN: 1096-0910.

Reinfeld BI, Rathmell WK. Untangling ccRCC prognosis with SLINKY [editorial]. Oncotarget [print-electronic]. 2017 Feb 2/20/2017; PMID: 28220033, PII: 15536, DOI: 10.18632/oncotarget.15536, ISSN: 1949-2553.

Fishbein L, Leshchiner I, Walter V, Danilova L, Robertson AG, Johnson AR, Lichtenberg TM, Murray BA, Ghayee HK, Else T, Ling S, Jefferys SR, de Cubas AA, Wenz B, Korpershoek E, Amelio AL, Makowski L, Rathmell WK, Gimenez-Roqueplo AP, Giordano TJ, Asa SL, Tischler AS, , Pacak K, Nathanson KL, Wilkerson MD. Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. Cancer Cell [print-electronic]. 2017 Feb 2/13/2017; 31(2): 181-93. PMID: 28162975, PII: S1535-6108(17)30001-6, DOI: 10.1016/j.ccell.2017.01.001, ISSN: 1878-3686.

Murakami A, Wang L, Kalhorn S, Schraml P, Rathmell WK, Tan AC, Nemenoff R, Stenmark K, Jiang BH, Reyland ME, Heasley L, Hu CJ. Context-dependent role for chromatin remodeling component PBRM1/BAF180 in clear cell renal cell carcinoma. Oncogenesis. 2017 Jan 1/16/2017; 6(1): e287. PMID: 28092369, PMCID: PMC5294252, PII: oncsis201689, DOI: 10.1038/oncsis.2016.89.

Haake SM, Rathmell WK. Renal cancer subtypes: Should we be lumping or splitting for therapeutic decision making?. Cancer [print-electronic]. 2017 Jan 1/1/2017; 123(2): 200-9. PMID: 27861752, PMCID: PMC5222778, DOI: 10.1002/cncr.30314, ISSN: 1097-0142.

Beckermann KE, Jolly PC, Kim JY, Bordeaux J, Puzanov I, Rathmell WK, Johnson DB. Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma. J Immunother Cancer. 2017; 5: 1. PMID: 28105368, PMCID: PMC5240268, PII: 206, DOI: 10.1186/s40425-016-0206-1, ISSN: 2051-1426.

Siska PJ, Johnpulle RAN, Zhou A, Bordeaux J, Kim JY, Dabbas B, Dakappagari N, Rathmell JC, Rathmell WK, Morgans AK, Balko JM, Johnson DB. Deep exploration of the immune infiltrate and outcome prediction in testicular cancer by quantitative multiplexed immunohistochemistry and gene expression profiling. Oncoimmunology. 2017; 6(4): e1305535. PMID: 28507813, PMCID: PMC5414873, PII: 1305535, DOI: 10.1080/2162402X.2017.1305535, ISSN: 2162-4011.

Weyandt JD, Thompson CB, Giaccia AJ, Rathmell WK. Metabolic Alterations in Cancer and Their Potential as Therapeutic Targets. Am Soc Clin Oncol Educ Book. 2017; 37: 825-32. PMID: 28561705, PII: 175561, DOI: 10.14694/EDBK_175561, ISSN: 1548-8756.

Shah AY, Karam JA, Malouf GG, Rao P, Lim ZD, Jonasch E, Xiao L, Gao J, Vaishampayan UN, Heng DY, Plimack ER, Guancial EA, Fung C, Lowas SR, Tamboli P, Sircar K, Matin SF, Kimryn Rathmell W, Wood CG, Tannir NM. Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study. BJU Int [print-electronic]. 2016 Nov 11/8/2016; PMID: 27860149, DOI: 10.1111/bju.13705, ISSN: 1464-410X.

Park IY, Chowdhury P, Tripathi DN, Powell RT, Dere R, Terzo EA, Rathmell WK, Walker CL. Methylated a-tubulin antibodies recognize a new microtubule modification on mitotic microtubules. MAbs [print-electronic]. 2016 Sep 9/3/2016; 0. PMID: 27594515, DOI: 10.1080/19420862.2016.1228505, ISSN: 1942-0870.

De Velasco G, Miao DD, Voss MH, Hakimi AA, Hsieh JJ, Tannir NM, Tamboli P, Appleman LJ, Rathmell WK, Van Allen E, Choueiri TK. Tumor mutational load and immune parameters across metastatic Renal Cell Carcinoma (mRCC) risk groups. Cancer Immunol Res [print-electronic]. 2016 Aug 8/18/2016; PMID: 27538576, PII: 2326-6066.CIR-16-0110, DOI: 10.1158/2326-6066.CIR-16-0110, ISSN: 2326-6074.

Hacker KE, Fahey CC, Shinsky SA, Chiang YJ, DiFiore JV, Jha DK, Vo AH, Shavit JA, Davis IJ, Strahl BD, Rathmell WK. Structure/Function Analysis of Recurrent Mutations in SETD2 Reveals a Critical and Conserved Role for a SET Domain Residue in Maintaining Protein Stability and H3K36 Trimethylation. J. Biol. Chem [print-electronic]. 2016 Aug 8/15/2016; PMID: 27528607, PII: M116.739375, DOI: 10.1074/jbc.M116.739375, ISSN: 1083-351X.

Park IY, Powell RT, Tripathi DN, Dere R, Ho TH, Blasius TL, Chiang YC, Davis IJ, Fahey CC, Hacker KE, Verhey KJ, Bedford MT, Jonasch E, Rathmell WK, Walker CL. Dual Chromatin and Cytoskeletal Remodeling by SETD2. Cell. 2016 Aug 8/11/2016; 166(4): 950-62. PMID: 27518565, PII: S0092-8674(16)30911-4, DOI: 10.1016/j.cell.2016.07.005, ISSN: 1097-4172.

Haake SM, Weyandt JD, Rathmell WK. Insights into the Genetic Basis of the Renal Cell Carcinomas from The Cancer Genome Atlas. Mol. Cancer Res [print-electronic]. 2016 Jul; 14(7): 589-98. PMID: 27330105, PMCID: PMC4955752, PII: 1541-7786.MCR-16-0115, DOI: 10.1158/1541-7786.MCR-16-0115, ISSN: 1557-3125.

Chism DD, Rathmell WK. Kidney cancer: Rest ASSUREd, much can be learned from adjuvant studies in renal cancer. Nat Rev Nephrol [print-electronic]. 2016 Jun; 12(6): 317-8. PMID: 27108841, PMCID: PMC4871728, PII: nrneph.2016.58, DOI: 10.1038/nrneph.2016.58, ISSN: 1759-507X.

Haake SM, Li J, Bai Y, Kinose F, Fang B, Welsh EA, Zent R, Dhillon J, Pow-Sang JM, Chen YA, Koomen JM, Rathmell WK, Fishman M, Haura EB. Tyrosine Kinase Signaling in Clear Cell and Papillary Renal Cell Carcinoma Revealed by Mass Spectrometry-Based Phosphotyrosine Proteomics. Clin. Cancer Res [print-electronic]. 2016 May 5/24/2016; PMID: 27220961, PII: 1078-0432.CCR-15-1673, DOI: 10.1158/1078-0432.CCR-15-1673, ISSN: 1078-0432.

Kishton RJ, Barnes CE, Nichols AG, Cohen S, Gerriets VA, Siska PJ, Macintyre AN, Goraksha-Hicks P, de Cubas AA, Liu T, Warmoes MO, Abel ED, Yeoh AE, Gershon TR, Rathmell WK, Richards KL, Locasale JW, Rathmell JC. AMPK Is Essential to Balance Glycolysis and Mitochondrial Metabolism to Control T-ALL Cell Stress and Survival. Cell Metab. 2016 Apr 4/12/2016; 23(4): 649-62. PMID: 27076078, PMCID: PMC4832577, PII: S1550-4131(16)30111-5, DOI: 10.1016/j.cmet.2016.03.008, ISSN: 1932-7420.

Brooks SA, Khandani A, Fielding J, Lin W, Sills T, Lee Y, Arreola A, Milowsky MI, Wallen EM, Woods ME, Smith AB, Nielsen ME, Parker JS, Lalush DS, Rathmell WK. Alternate metabolic programs define regional variation of relevant biological features in renal cell carcinoma progression. Clin. Cancer Res [print-electronic]. 2016 Jan 1/19/2016; PMID: 26787754, PII: 1078-0432.CCR-15-2115, DOI: 10.1158/1078-0432.CCR-15-2115, ISSN: 1078-0432.

Block KI, Gyllenhaal C, Lowe L, Amedei A, Amin AR, Amin A, Aquilano K, Arbiser J, Arreola A, Arzumanyan A, Ashraf SS, Azmi AS, Benencia F, Bhakta D, Bilsland A, Bishayee A, Blain SW, Block PB, Boosani CS, Carey TE, Carnero A, Carotenuto M, Casey SC, Chakrabarti M, Chaturvedi R, Chen GZ, Chen H, Chen S, Chen YC, Choi BK, Ciriolo MR, Coley HM, Collins AR, Connell M, Crawford S, Curran CS, Dabrosin C, Damia G, Dasgupta S, DeBerardinis RJ, Decker WK, Dhawan P, Diehl AM, Dong JT, Dou QP, Drew JE, Elkord E, El-Rayes B, Feitelson MA, Felsher DW, Ferguson LR, Fimognari C, Firestone GL, Frezza C, Fujii H, Fuster MM, Generali D, Georgakilas AG, Gieseler F, Gilbertson M, Green MF, Grue B, Guha G, Halicka D, Helferich WG, Heneberg P, Hentosh P, Hirschey MD, Hofseth LJ, Holcombe RF, Honoki K, Hsu HY, Huang GS, Jensen LD, Jiang WG, Jones LW, Karpowicz PA, Keith WN, Kerkar SP, Khan GN, Khatami M, Ko YH, Kucuk O, Kulathinal RJ, Kumar NB, Kwon BS, Le A, Lea MA, Lee HY, Lichtor T, Lin LT, Locasale JW, Lokeshwar BL, Longo VD, Lyssiotis CA, MacKenzie KL, Malhotra M, Marino M, Martinez-Chantar ML, Matheu A, Maxwell C, McDonnell E, Meeker AK, Mehrmohamadi M, Mehta K, Michelotti GA, Mohammad RM, Mohammed SI, Morre DJ, Muralidhar V, Muqbil I, Murphy MP, Nagaraju GP, Nahta R, Niccolai E, Nowsheen S, Panis C, Pantano F, Parslow VR, Pawelec G, Pedersen PL, Poore B, Poudyal D, Prakash S, Prince M, Raffaghello L, Rathmell JC, Rathmell WK, Ray SK, Reichrath J, Rezazadeh S, Ribatti D, Ricciardiello L, Robey RB, Rodier F, Rupasinghe HP, Russo GL, Ryan EP, Samadi AK, Sanchez-Garcia I, Sanders AJ, Santini D, Sarkar M, Sasada T, Saxena NK, Shackelford RE, Shantha Kumara HM, Sharma D, Shin DM, Sidransky D, Siegelin MD, Signori E, Singh N, Sivanand S, Sliva D, Smythe C, Spagnuolo C, Stafforini DM, Stagg J, Subbarayan PR, Sundin T, Talib WH, Thompson SK, Tran PT, Ungefroren H, Vander Heiden MG, Venkateswaran V, Vinay DS, Vlachostergios PJ, Wang Z, Wellen KE, Whelan RL, Yang ES, Yang H, Yang X, Yaswen P, Yedjou C, Yin X, Zhu J, Zollo M. Designing a broad-spectrum integrative approach for cancer prevention and treatment. Semin. Cancer Biol. 2015 Dec; 35 Suppl: S276-304. PMID: 26590477, PII: S1044-579X(15)00088-7, DOI: 10.1016/j.semcancer.2015.09.007, ISSN: 1096-3650.

Wang Z, Dabrosin C, Yin X, Fuster MM, Arreola A, Rathmell WK, Generali D, Nagaraju GP, El-Rayes B, Ribatti D, Chen YC, Honoki K, Fujii H, Georgakilas AG, Nowsheen S, Amedei A, Niccolai E, Amin A, Ashraf SS, Helferich B, Yang X, Guha G, Bhakta D, Ciriolo MR, Aquilano K, Chen S, Halicka D, Mohammed SI, Azmi AS, Bilsland A, Keith WN, Jensen LD. Broad targeting of angiogenesis for cancer prevention and therapy. Semin. Cancer Biol [print-electronic]. 2015 Dec; 35 Suppl: S224-43. PMID: 25600295, PII: S1044-579X(15)00002-4, DOI: 10.1016/j.semcancer.2015.01.001, ISSN: 1096-3650.

Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, Davis C, Wheeler DA, Murray BA, Schmidt L, Vocke CD, Peto M, Al Mamun AA, Shinbrot E, Sethi A, Brooks S, Rathmell WK, Brooks AN, Hoadley KA, Robertson AG, Brooks D, Bowlby R, Sadeghi S, Shen H, Weisenberger DJ, Bootwalla M, Baylin SB, Laird PW, Cherniack AD, Saksena G, Haake S, Li J, Liang H, Lu Y, Mills GB, Akbani R, Leiserson MD, Raphael BJ, Anur P, Bottaro D, Albiges L, Barnabas N, Choueiri TK, Czerniak B, Godwin AK, Hakimi AA, Ho TH, Hsieh J, Ittmann M, Kim WY, Krishnan B, Merino MJ, Shaw KR, Reuter VE, Reznik E, Shelley CS, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Tickoo S, Burnett K, Crain D, Gardner J, Lau K, Mallery D, Morris S, Paulauskis JD, Penny RJ, Shelton C, Shelton WT, Sherman M, Thompson E, Yena P, Avedon MT, Bowen J, Gastier-Foster JM, Gerken M, Leraas KM, Lichtenberg TM, Ramirez NC, Santos T, Wise L, Zmuda E, Demchok JA, Felau I, Hutter CM, Sheth M, Sofia HJ, Tarnuzzer R, Wang Z, Yang L, Zenklusen JC, Zhang J, Ayala B, Baboud J, Chudamani S, Liu J, Lolla L, Naresh R, Pihl T, Sun Q, Wan Y, Wu Y, Ally A, Balasundaram M, Balu S, Beroukhim R, Bodenheimer T, Buhay C, Butterfield YS, Carlsen R, Carter SL, Chao H, Chuah E, Clarke A, Covington KR, Dahdouli M, Dewal N, Dhalla N, Doddapaneni HV, Drummond JA, Gabriel SB, Gibbs RA, Guin R, Hale W, Hawes A, Hayes DN, Holt RA, Hoyle AP, Jefferys SR, Jones SJ, Jones CD, Kalra D, Kovar C, Lewis L, Li J, Ma Y, Marra MA, Mayo M, Meng S, Meyerson M, Mieczkowski PA, Moore RA, Morton D, Mose LE, Mungall AJ, Muzny D, Parker JS, Perou CM, Roach J, Schein JE, Schumacher SE, Shi Y, Simons JV, Sipahimalani P, Skelly T, Soloway MG, Sougnez C, Tam A, Tan D, Thiessen N, Veluvolu U, Wang M, Wilkerson MD, Wong T, Wu J, Xi L, Zhou J, Bedford J, Chen F, Fu Y, Gerstein M, Haussler D, Kasaian K, Lai P, Ling S, Radenbaugh A, Van Den Berg D, Weinstein JN, Zhu J, Albert M, Alexopoulou I, Andersen JJ, Auman JT, Bartlett J, Bastacky S, Bergsten J, Blute ML, Boice L, Bollag RJ, Boyd J, Castle E, Chen YB, Cheville JC, Curley E, Davies B, DeVolk A, Dhir R, Dike L, Eckman J, Engel J, Harr J, Hrebinko R, Huang M, Huelsenbeck-Dill L, Iacocca M, Jacobs B, Lobis M, Maranchie JK, McMeekin S, Myers J, Nelson J, Parfitt J, Parwani A, Petrelli N, Rabeno B, Roy S, Salner AL, Slaton J, Stanton M, Thompson RH, Thorne L, Tucker K, Weinberger PM, Winemiller C, Zach LA, Zuna R, . Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N. Engl. J. Med [print-electronic]. 2015 Nov 11/4/2015; PMID: 26536169, DOI: 10.1056/NEJMoa1505917, ISSN: 1533-4406.

Haake SM, Brooks SA, Welsh E, Fulp WJ, Chen DT, Dhillon J, Haura E, Sexton W, Spiess PE, Pow-Sang J, Rathmell WK, Fishman M. Patients with ClearCode34-identified molecular subtypes of clear cell renal cell carcinoma represent unique populations with distinct comorbidities. Urol. Oncol [print-electronic]. 2015 Nov 11/3/2015; PMID: 26546482, PII: S1078-1439(15)00480-9, DOI: 10.1016/j.urolonc.2015.09.015, ISSN: 1873-2496.

Haake SM, Brooks SA, Welsh E, Fulp WJ, Chen DT, Dhillon J, Haura E, Sexton W, Spiess PE, Pow-Sang J, Rathmell WK, Fishman M. Patients with ClearCode34-identified molecular subtypes of clear cell renal cell carcinoma represent unique populations with distinct comorbidities. Urol. Oncol [print-electronic]. 2015 Nov 11/3/2015; PMID: 26546482, PII: S1078-1439(15)00480-9, DOI: 10.1016/j.urolonc.2015.09.015, ISSN: 1873-2496.

Chang EH, Chong WK, Kasoji S, Dayton PA, Rathmell WK. Management of Indeterminate Cystic Kidney Lesions: Review of Contrast-Enhanced Ultrasound as a Diagnostic Tool. Urology [print-electronic]. 2015 Oct 10/16/2015; PMID: 26483268, PII: S0090-4295(15)00938-3, DOI: 10.1016/j.urology.2015.10.002, ISSN: 1527-9995.

Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, Zhang H, McLellan M, Yau C, Kandoth C, Bowlby R, Shen H, Hayat S, Fieldhouse R, Lester SC, Tse GM, Factor RE, Collins LC, Allison KH, Chen YY, Jensen K, Johnson NB, Oesterreich S, Mills GB, Cherniack AD, Robertson G, Benz C, Sander C, Laird PW, Hoadley KA, King TA, , Perou CM. Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. Cell. 2015 Oct 10/8/2015; 163(2): 506-19. PMID: 26451490, PMCID: PMC4603750, PII: S0092-8674(15)01195-2, DOI: 10.1016/j.cell.2015.09.033, ISSN: 1097-4172.

Rose TL, Deal AM, Basch E, Godley PA, Rathmell WK, Kim WY, Whang YE, Dunn MW, Wang A, Chen RC, Nielsen ME, Pruthi RS, Wallen EM, Woods ME, Smith AB, Milowsky MI. Neoadjuvant chemotherapy administration and time to cystectomy for muscle-invasive bladder cancer: An evaluation of transitions between academic and community settings. Urol. Oncol [print-electronic]. 2015 Sep; 33(9): 386.e1-6. PMID: 26122712, PII: S1078-1439(15)00272-0, DOI: 10.1016/j.urolonc.2015.05.028, ISSN: 1873-2496.

, Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, Cooper LA, Rheinbay E, Miller CR, Vitucci M, Morozova O, Robertson AG, Noushmehr H, Laird PW, Cherniack AD, Akbani R, Huse JT, Ciriello G, Poisson LM, Barnholtz-Sloan JS, Berger MS, Brennan C, Colen RR, Colman H, Flanders AE, Giannini C, Grifford M, Iavarone A, Jain R, Joseph I, Kim J, Kasaian K, Mikkelsen T, Murray BA, O'Neill BP, Pachter L, Parsons DW, Sougnez C, Sulman EP, Vandenberg SR, Van Meir EG, von Deimling A, Zhang H, Crain D, Lau K, Mallery D, Morris S, Paulauskis J, Penny R, Shelton T, Sherman M, Yena P, Black A, Bowen J, Dicostanzo K, Gastier-Foster J, Leraas KM, Lichtenberg TM, Pierson CR, Ramirez NC, Taylor C, Weaver S, Wise L, Zmuda E, Davidsen T, Demchok JA, Eley G, Ferguson ML, Hutter CM, Mills Shaw KR, Ozenberger BA, Sheth M, Sofia HJ, Tarnuzzer R, Wang Z, Yang L, Zenklusen JC, Ayala B, Baboud J, Chudamani S, Jensen MA, Liu J, Pihl T, Raman R, Wan Y, Wu Y, Ally A, Auman JT, Balasundaram M, Balu S, Baylin SB, Beroukhim R, Bootwalla MS, Bowlby R, Bristow CA, Brooks D, Butterfield Y, Carlsen R, Carter S, Chin L, Chu A, Chuah E, Cibulskis K, Clarke A, Coetzee SG, Dhalla N, Fennell T, Fisher S, Gabriel S, Getz G, Gibbs R, Guin R, Hadjipanayis A, Hayes DN, Hinoue T, Hoadley K, Holt RA, Hoyle AP, Jefferys SR, Jones S, Jones CD, Kucherlapati R, Lai PH, Lander E, Lee S, Lichtenstein L, Ma Y, Maglinte DT, Mahadeshwar HS, Marra MA, Mayo M, Meng S, Meyerson ML, Mieczkowski PA, Moore RA, Mose LE, Mungall AJ, Pantazi A, Parfenov M, Park PJ, Parker JS, Perou CM, Protopopov A, Ren X, Roach J, Sabedot TS, Schein J, Schumacher SE, Seidman JG, Seth S, Shen H, Simons JV, Sipahimalani P, Soloway MG, Song X, Sun H, Tabak B, Tam A, Tan D, Tang J, Thiessen N, Triche T, Van Den Berg DJ, Veluvolu U, Waring S, Weisenberger DJ, Wilkerson MD, Wong T, Wu J, Xi L, Xu AW, Yang L, Zack TI, Zhang J, Aksoy BA, Arachchi H, Benz C, Bernard B, Carlin D, Cho J, DiCara D, Frazer S, Fuller GN, Gao J, Gehlenborg N, Haussler D, Heiman DI, Iype L, Jacobsen A, Ju Z, Katzman S, Kim H, Knijnenburg T, Kreisberg RB, Lawrence MS, Lee W, Leinonen K, Lin P, Ling S, Liu W, Liu Y, Liu Y, Lu Y, Mills G, Ng S, Noble MS, Paull E, Rao A, Reynolds S, Saksena G, Sanborn Z, Sander C, Schultz N, Senbabaoglu Y, Shen R, Shmulevich I, Sinha R, Stuart J, Sumer SO, Sun Y, Tasman N, Taylor BS, Voet D, Weinhold N, Weinstein JN, Yang D, Yoshihara K, Zheng S, Zhang W, Zou L, Abel T, Sadeghi S, Cohen ML, Eschbacher J, Hattab EM, Raghunathan A, Schniederjan MJ, Aziz D, Barnett G, Barrett W, Bigner DD, Boice L, Brewer C, Calatozzolo C, Campos B, Carlotti CG, Chan TA, Cuppini L, Curley E, Cuzzubbo S, Devine K, DiMeco F, Duell R, Elder JB, Fehrenbach A, Finocchiaro G, Friedman W, Fulop J, Gardner J, Hermes B, Herold-Mende C, Jungk C, Kendler A, Lehman NL, Lipp E, Liu O, Mandt R, McGraw M, Mclendon R, McPherson C, Neder L, Nguyen P, Noss A, Nunziata R, Ostrom QT, Palmer C, Perin A, Pollo B, Potapov A, Potapova O, Rathmell WK, Rotin D, Scarpace L, Schilero C, Senecal K, Shimmel K, Shurkhay V, Sifri S, Singh R, Sloan AE, Smolenski K, Staugaitis SM, Steele R, Thorne L, Tirapelli DP, Unterberg A, Vallurupalli M, Wang Y, Warnick R, Williams F, Wolinsky Y, Bell S, Rosenberg M, Stewart C, Huang F, Grimsby JL, Radenbaugh AJ, Zhang J. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N. Engl. J. Med [print-electronic]. 2015 Jun 6/25/2015; 372(26): 2481-98. PMID: 26061751, PMCID: PMC4530011, DOI: 10.1056/NEJMoa1402121, ISSN: 1533-4406.

Goodson WH, Lowe L, Carpenter DO, Gilbertson M, Manaf Ali A, Lopez de Cerain Salsamendi A, Lasfar A, Carnero A, Azqueta A, Amedei A, Charles AK, Collins AR, Ward A, Salzberg AC, Colacci A, Olsen AK, Berg A, Barclay BJ, Zhou BP, Blanco-Aparicio C, Baglole CJ, Dong C, Mondello C, Hsu CW, Naus CC, Yedjou C, Curran CS, Laird DW, Koch DC, Carlin DJ, Felsher DW, Roy D, Brown DG, Ratovitski E, Ryan EP, Corsini E, Rojas E, Moon EY, Laconi E, Marongiu F, Al-Mulla F, Chiaradonna F, Darroudi F, Martin FL, Van Schooten FJ, Goldberg GS, Wagemaker G, Nangami GN, Calaf GM, Williams G, Wolf GT, Koppen G, Brunborg G, Lyerly HK, Krishnan H, Ab Hamid H, Yasaei H, Sone H, Kondoh H, Salem HK, Hsu HY, Park HH, Koturbash I, Miousse IR, Scovassi AI, Klaunig JE, Vondrácek J, Raju J, Roman J, Wise JP, Whitfield JR, Woodrick J, Christopher JA, Ochieng J, Martinez-Leal JF, Weisz J, Kravchenko J, Sun J, Prudhomme KR, Narayanan KB, Cohen-Solal KA, Moorwood K, Gonzalez L, Soucek L, Jian L, D'Abronzo LS, Lin LT, Li L, Gulliver L, McCawley LJ, Memeo L, Vermeulen L, Leyns L, Zhang L, Valverde M, Khatami M, Romano MF, Chapellier M, Williams MA, Wade M, Manjili MH, Lleonart ME, Xia M, Gonzalez MJ, Karamouzis MV, Kirsch-Volders M, Vaccari M, Kuemmerle NB, Singh N, Cruickshanks N, Kleinstreuer N, van Larebeke N, Ahmed N, Ogunkua O, Krishnakumar PK, Vadgama P, Marignani PA, Ghosh PM, Ostrosky-Wegman P, Thompson PA, Dent P, Heneberg P, Darbre P, Sing Leung P, Nangia-Makker P, Cheng QS, Robey RB, Al-Temaimi R, Roy R, Andrade-Vieira R, Sinha RK, Mehta R, Vento R, Di Fiore R, Ponce-Cusi R, Dornetshuber-Fleiss R, Nahta R, Castellino RC, Palorini R, Abd Hamid R, Langie SA, Eltom SE, Brooks SA, Ryeom S, Wise SS, Bay SN, Harris SA, Papagerakis S, Romano S, Pavanello S, Eriksson S, Forte S, Casey SC, Luanpitpong S, Lee TJ, Otsuki T, Chen T, Massfelder T, Sanderson T, Guarnieri T, Hultman T, Dormoy V, Odero-Marah V, Sabbisetti V, Maguer-Satta V, Rathmell WK, Engström W, Decker WK, Bisson WH, Rojanasakul Y, Luqmani Y, Chen Z, Hu Z. Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead. Carcinogenesis. 2015 Jun; 36 Suppl 1: S254-96. PMID: 26106142, PMCID: PMC4480130, PII: bgv039, DOI: 10.1093/carcin/bgv039, ISSN: 1460-2180.

Debebe Z, Rathmell WK. Ror2 as a therapeutic target in cancer. Pharmacol. Ther [print-electronic]. 2015 Jun; 150: 143-8. PMID: 25614331, PII: S0163-7258(15)00030-3, DOI: 10.1016/j.pharmthera.2015.01.010, ISSN: 1879-016X.

Hu Z, Brooks SA, Dormoy V, Hsu CW, Hsu HY, Lin LT, Massfelder T, Rathmell WK, Xia M, Al-Mulla F, Al-Temaimi R, Amedei A, Brown DG, Prudhomme KR, Colacci A, Hamid RA, Mondello C, Raju J, Ryan EP, Woodrick J, Scovassi AI, Singh N, Vaccari M, Roy R, Forte S, Memeo L, Salem HK, Lowe L, Jensen L, Bisson WH, Kleinstreuer N. Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: focus on the cancer hallmark of tumor angiogenesis. Carcinogenesis. 2015 Jun; 36 Suppl 1: S184-202. PMID: 26106137, PMCID: PMC4492067, PII: bgv036, DOI: 10.1093/carcin/bgv036, ISSN: 1460-2180.

Fahey CC, Rathmell WK. A tale of two cancers: Complete genetic analysis of chromophobe renal cell carcinoma contrasts with clear cell renal cell carcinoma. Mol Cell Oncol. 2015 Apr; 2(2): e979686. PMID: 27308442, PMCID: PMC4904899, PII: 979686, DOI: 10.4161/23723556.2014.979686.

Sendor AB, Hacker KE, Chen S, Corona AL, Sen O, Chiang DY, Snavely A, Rogers AB, Montgomery SA, Rathmell WK, McRee AJ. Von Hippel-Lindau status influences phenotype of liver cancers arising from PTEN loss. Gastrointest Cancer. 2015 Feb 2/1/2015; 5: 61-71. PMID: 25844041, PMCID: PMC4383253, DOI: 10.2147/GICTT.S72274, ISSN: 1179-9919.

Rathmell KW, Chen F, Creighton CJ. Genomics of chromophobe renal cell carcinoma: implications from a rare tumor for pan-cancer studies. Oncoscience. 2015; 2(2): 81-90. PMID: 25859550, PMCID: PMC4381700, PII: 130, ISSN: 2331-4737.

Rathmell WK, Brooks SA, Parker JS, Nielsen ME. Reply to Alexander S. Parker, Brad C. Leibovich, Jeanette E. Eckel-Passow, John C. Cheville's letter to the editor re: Samira A. Brooks, A. Rose Brannon, Joel S. Parker, et al. ClearCode34: a prognostic risk predictor for localized clear cell renal cell carcinoma. Eur Urol 2014;66:77-84 [letter]. Eur. Urol [print-electronic]. 2014 Nov; 66(5): e92. PMID: 25037640, PMCID: PMC4294998, PII: S0302-2838(14)00630-7, DOI: 10.1016/j.eururo.2014.07.002, ISSN: 1873-7560.

Parfenov M, Pedamallu CS, Gehlenborg N, Freeman SS, Danilova L, Bristow CA, Lee S, Hadjipanayis AG, Ivanova EV, Wilkerson MD, Protopopov A, Yang L, Seth S, Song X, Tang J, Ren X, Zhang J, Pantazi A, Santoso N, Xu AW, Mahadeshwar H, Wheeler DA, Haddad RI, Jung J, Ojesina AI, Issaeva N, Yarbrough WG, Hayes DN, Grandis JR, El-Naggar AK, Meyerson M, Park PJ, Chin L, Seidman JG, Hammerman PS, Kucherlapati R, . Characterization of HPV and host genome interactions in primary head and neck cancers. Proc. Natl. Acad. Sci. U.S.A [print-electronic]. 2014 Oct 10/28/2014; 111(43): 15544-9. PMID: 25313082, PMCID: PMC4217452, PII: 1416074111, DOI: 10.1073/pnas.1416074111, ISSN: 1091-6490.

. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014 Oct 10/23/2014; 159(3): 676-90. PMID: 25417114, PMCID: PMC4243044, PII: S0092-8674(14)01238-0, DOI: 10.1016/j.cell.2014.09.050, ISSN: 1097-4172.

. Comprehensive molecular characterization of gastric adenocarcinoma. Nature [print-electronic]. 2014 Sep 9/11/2014; 513(7517): 202-9. PMID: 25079317, PMCID: PMC4170219, PII: nature13480, DOI: 10.1038/nature13480, ISSN: 1476-4687.

Davis CF, Ricketts CJ, Wang M, Yang L, Cherniack AD, Shen H, Buhay C, Kang H, Kim SC, Fahey CC, Hacker KE, Bhanot G, Gordenin DA, Chu A, Gunaratne PH, Biehl M, Seth S, Kaipparettu BA, Bristow CA, Donehower LA, Wallen EM, Smith AB, Tickoo SK, Tamboli P, Reuter V, Schmidt LS, Hsieh JJ, Choueiri TK, Hakimi AA, , Chin L, Meyerson M, Kucherlapati R, Park WY, Robertson AG, Laird PW, Henske EP, Kwiatkowski DJ, Park PJ, Morgan M, Shuch B, Muzny D, Wheeler DA, Linehan WM, Gibbs RA, Rathmell WK, Creighton CJ. The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell [print-electronic]. 2014 Sep 9/8/2014; 26(3): 319-30. PMID: 25155756, PMCID: PMC4160352, PII: S1535-6108(14)00304-3, DOI: 10.1016/j.ccr.2014.07.014, ISSN: 1878-3686.

Khandani AH, Rathmell WK, Wallen EM, Ivanovic M. PET/CT with (124)I-cG250: great potential and some open questions. AJR Am J Roentgenol. 2014 Aug; 203(2): 261-2. PMID: 25055257, DOI: 10.2214/AJR.14.12490, ISSN: 1546-3141.

. Comprehensive molecular profiling of lung adenocarcinoma. Nature [print-electronic]. 2014 Jul 7/31/2014; 511(7511): 543-50. PMID: 25079552, PMCID: PMC4231481, PII: nature13385, DOI: 10.1038/nature13385, ISSN: 1476-4687.

Brooks SA, Brannon AR, Parker JS, Fisher JC, Sen O, Kattan MW, Hakimi AA, Hsieh JJ, Choueiri TK, Tamboli P, Maranchie JK, Hinds P, Miller CR, Nielsen ME, Rathmell WK. ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma. Eur. Urol [print-electronic]. 2014 Jul; 66(1): 77-84. PMID: 24613583, PMCID: PMC4058355, PII: S0302-2838(14)00164-X, DOI: 10.1016/j.eururo.2014.02.035, ISSN: 1873-7560.

Chism DD, Rathmell WK. Seeing the forest for the trees: kidney oncogenomes in relation to therapeutic outcomes. Clin. Cancer Res [print-electronic]. 2014 Apr 4/1/2014; 20(7): 1721-3. PMID: 24634386, PMCID: PMC4077661, PII: 1078-0432.CCR-14-0056, DOI: 10.1158/1078-0432.CCR-14-0056, ISSN: 1078-0432.

Jagsi R, Spence R, Rathmell WK, Bradbury A, Peppercorn J, Grubbs S, Moy B. Ethical considerations for the clinical oncologist in an era of oncology drug shortages. Oncologist [print-electronic]. 2014 Feb; 19(2): 186-92. PMID: 24449096, PMCID: PMC3926786, PII: theoncologist.2013-0301, DOI: 10.1634/theoncologist.2013-0301, ISSN: 1549-490X.

Simon JM, Hacker KE, Singh D, Brannon AR, Parker JS, Weiser M, Ho TH, Kuan PF, Jonasch E, Furey TS, Prins JF, Lieb JD, Rathmell WK, Davis IJ. Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects. Genome Res [print-electronic]. 2014 Feb; 24(2): 241-50. PMID: 24158655, PMCID: PMC3912414, PII: gr.158253.113, DOI: 10.1101/gr.158253.113, ISSN: 1549-5469.

Gallagher SA, Smith AB, Matthews JE, Potter CW, Woods ME, Raynor M, Wallen EM, Rathmell WK, Whang YE, Kim WY, Godley PA, Chen RC, Wang A, You C, Barocas DA, Pruthi RS, Nielsen ME, Milowsky MI. Roadmap for the development of the University of North Carolina at Chapel Hill Genitourinary OncoLogy Database--UNC GOLD. Urol. Oncol [print-electronic]. 2014 Jan; 32(1): 32.e1-9. PMID: 23434424, PMCID: PMC4058502, PII: S1078-1439(12)00425-5, DOI: 10.1016/j.urolonc.2012.11.019, ISSN: 1873-2496.

Rasmussen NR, Debebe Z, Wright TM, Brooks SA, Sendor AB, Brannon AR, Hakimi AA, Hsieh JJ, Choueiri TK, Tamboli P, Maranchie JK, Hinds P, Wallen EM, Simpson C, Norris JL, Janzen WP, Rathmell WK. Expression of Ror2 mediates invasive phenotypes in renal cell carcinoma. PLoS ONE. 2014; 9(12): e116101. PMID: 25542006, PMCID: PMC4277431, PII: PONE-D-14-13817, DOI: 10.1371/journal.pone.0116101, ISSN: 1932-6203.

Begg CB, Seshan VE, Zabor EC, Furberg H, Arora A, Shen R, Maranchie JK, Nielsen ME, Rathmell WK, Signoretti S, Tamboli P, Karam JA, Choueiri TK, Hakimi AA, Hsieh JJ. Genomic investigation of etiologic heterogeneity: methodologic challenges. BMC Med Res Methodol. 2014; 14: 138. PMID: 25532962, PMCID: PMC4292824, PII: 1471-2288-14-138, DOI: 10.1186/1471-2288-14-138, ISSN: 1471-2288.

Jonasch E, Gao J, Rathmell WK. Renal cell carcinoma. BMJ. 2014; 349: g4797. PMID: 25385470, ISSN: 1756-1833.

Arreola A, Cowey CL, Coloff JL, Rathmell JC, Rathmell WK. HIF1a and HIF2a exert distinct nutrient preferences in renal cells. PLoS ONE. 2014; 9(5): e98705. PMID: 24879016, PMCID: PMC4039535, PII: PONE-D-13-47383, DOI: 10.1371/journal.pone.0098705, ISSN: 1932-6203.

Olshan AF, Kuo TM, Meyer AM, Nielsen ME, Purdue MP, Rathmell WK. Racial difference in histologic subtype of renal cell carcinoma. Cancer Med [print-electronic]. 2013 Oct; 2(5): 744-9. PMID: 24403240, PMCID: PMC3892806, DOI: 10.1002/cam4.110, ISSN: 2045-7634.

Desimone MC, Rathmell WK, Threadgill DW. Pleiotropic effects of the trichloroethylene-associated P81S VHL mutation on metabolism, apoptosis, and ATM-mediated DNA damage response. J. Natl. Cancer Inst [print-electronic]. 2013 Sep 9/18/2013; 105(18): 1355-64. PMID: 23990666, PMCID: PMC3776265, PII: djt226, DOI: 10.1093/jnci/djt226, ISSN: 1460-2105.

Rasmussen NR, Wright TM, Brooks SA, Hacker KE, Debebe Z, Sendor AB, Walker MP, Major MB, Green J, Wahl GM, Rathmell WK. Receptor tyrosine kinase-like orphan receptor 2 (Ror2) expression creates a poised state of Wnt signaling in renal cancer. J. Biol. Chem [print-electronic]. 2013 Sep 9/6/2013; 288(36): 26301-10. PMID: 23893409, PMCID: PMC3764835, PII: M113.466086, DOI: 10.1074/jbc.M113.466086, ISSN: 1083-351X.

Chen JL, Appelbaum DE, Kocherginsky M, Cowey CL, Rathmell WK, McDermott DF, Stadler WM. FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer. Cancer Med [print-electronic]. 2013 Aug; 2(4): 545-52. PMID: 24156027, PMCID: PMC3799289, DOI: 10.1002/cam4.102, ISSN: 2045-7634.

Keefe SM, Nathanson KL, Rathmell WK. The molecular biology of renal cell carcinoma. Semin. Oncol. 2013 Aug; 40(4): 421-8. PMID: 23972705, PII: S0093-7754(13)00081-X, DOI: 10.1053/j.seminoncol.2013.05.006, ISSN: 1532-8708.

Lockhart AC, Brose MS, Kim ES, Johnson DH, Peppercorn JM, Michels DL, Storm CD, Schuchter LM, Rathmell WK. Physician and stakeholder perceptions of conflict of interest policies in oncology. J. Clin. Oncol [print-electronic]. 2013 May 5/1/2013; 31(13): 1677-82. PMID: 23530092, PMCID: PMC4525129, PII: JCO.2012.47.5475, DOI: 10.1200/JCO.2012.47.5475, ISSN: 1527-7755.

Gameiro PA, Yang J, Metelo AM, Pérez-Carro R, Baker R, Wang Z, Arreola A, Rathmell WK, Olumi A, López-Larrubia P, Stephanopoulos G, Iliopoulos O. In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation. Cell Metab. 2013 Mar 3/5/2013; 17(3): 372-85. PMID: 23473032, PMCID: PMC4003458, PII: S1550-4131(13)00050-8, DOI: 10.1016/j.cmet.2013.02.002, ISSN: 1932-7420.

Valgus J, Singer EA, Berry SR, Rathmell WK. Ethical challenges: managing oncology drug shortages. J Oncol Pract. 2013 Mar; 9(2): e21-3. PMID: 23814521, PMCID: PMC3595447, PII: 3818781, DOI: 10.1200/JOP.2012.000779, ISSN: 1935-469X.

Kapur P, Peña-Llopis S, Christie A, Zhrebker L, Pavía-Jiménez A, Rathmell WK, Xie XJ, Brugarolas J. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. Lancet Oncol [print-electronic]. 2013 Feb; 14(2): 159-67. PMID: 23333114, PMCID: PMC4674067, PII: S1470-2045(12)70584-3, DOI: 10.1016/S1470-2045(12)70584-3, ISSN: 1474-5488.

Whang YE, Armstrong AJ, Rathmell WK, Godley PA, Kim WY, Pruthi RS, Wallen EM, Crane JM, Moore DT, Grigson G, Morris K, Watkins CP, George DJ. A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer. Urol. Oncol [print-electronic]. 2013 Jan; 31(1): 82-6. PMID: 21396844, PII: S1078-1439(10)00299-1, DOI: 10.1016/j.urolonc.2010.09.018, ISSN: 1873-2496.

Chen RC, Rosenman JG, Hoffman LG, Chiu WK, Wang AZ, Pruthi RS, Wallen EM, Crane JM, Kim WY, Rathmell WK, Godley PA, Whang YE. Phase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for high-risk prostate cancer. BJU Int [print-electronic]. 2012 Dec; 110(11 Pt B): E721-6. PMID: 23016517, DOI: 10.1111/j.1464-410X.2012.11536.x, ISSN: 1464-410X.

Linehan WM, Rathmell WK. Kidney cancer. Urol. Oncol. 2012 Nov; 30(6): 948-51. PMID: 23218074, PMCID: PMC4419144, PII: S1078-1439(12)00321-3, DOI: 10.1016/j.urolonc.2012.08.021, ISSN: 1873-2496.

Khandani AH, Cowey CL, Moore DT, Gohil H, Rathmell WK. Primary renal cell carcinoma: relationship between 18F-FDG uptake and response to neoadjuvant sorafenib. Nucl Med Commun. 2012 Sep; 33(9): 967-73. PMID: 22714005, DOI: 10.1097/MNM.0b013e3283561837, ISSN: 1473-5628.

Khandani AH, Rathmell WK. Positron emission tomography in renal cell carcinoma: an imaging biomarker in development. Semin Nucl Med. 2012 Jul; 42(4): 221-30. PMID: 22681671, PII: S0001-2998(12)00022-0, DOI: 10.1053/j.semnuclmed.2012.02.002, ISSN: 1558-4623.

Jonasch E, Futreal PA, Davis IJ, Bailey ST, Kim WY, Brugarolas J, Giaccia AJ, Kurban G, Pause A, Frydman J, Zurita AJ, Rini BI, Sharma P, Atkins MB, Walker CL, Rathmell WK. State of the science: an update on renal cell carcinoma. Mol. Cancer Res [print-electronic]. 2012 Jul; 10(7): 859-80. PMID: 22638109, PMCID: PMC3399969, PII: 1541-7786.MCR-12-0117, DOI: 10.1158/1541-7786.MCR-12-0117, ISSN: 1557-3125.

Manvar AM, Rathmell WK, Ferguson J, Pruthi RS, Nielsen ME, Wallen EM, Nolan N, Raynor MC. Carcinoma in a cadaveric transplant kidney. Urology [print-electronic]. 2012 Apr; 79(4): 758-60. PMID: 22014593, PII: S0090-4295(11)02320-X, DOI: 10.1016/j.urology.2011.08.044, ISSN: 1527-9995.

Brannon AR, Haake SM, Hacker KE, Pruthi RS, Wallen EM, Nielsen ME, Rathmell WK. Meta-analysis of clear cell renal cell carcinoma gene expression defines a variant subgroup and identifies gender influences on tumor biology. Eur. Urol [print-electronic]. 2012 Feb; 61(2): 258-68. PMID: 22030119, PMCID: PMC3244546, PII: S0302-2838(11)01107-9, DOI: 10.1016/j.eururo.2011.10.007, ISSN: 1873-7560.

Gamper AM, Qiao X, Kim J, Zhang L, DeSimone MC, Rathmell WK, Wan Y. Regulation of KLF4 turnover reveals an unexpected tissue-specific role of pVHL in tumorigenesis. Mol. Cell. 2012 Jan 1/27/2012; 45(2): 233-43. PMID: 22284679, PMCID: PMC3982234, PII: S1097-2765(12)00004-4, DOI: 10.1016/j.molcel.2011.11.031, ISSN: 1097-4164.

Kim WY, Whang YE, Pruthi RS, Baggstrom MQ, Rathmell WK, Rosenman JG, Wallen EM, Goyal LK, Grigson G, Watkins C, Godley PA. Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: a phase II trial. Urol. Oncol [print-electronic]. 2011 Nov; 29(6): 608-13. PMID: 20022268, PII: S1078-1439(09)00293-2, DOI: 10.1016/j.urolonc.2009.09.012, ISSN: 1873-2496.

Teng BL, Hacker KE, Chen S, Means AR, Rathmell WK. Tumor suppressive activity of prolyl isomerase Pin1 in renal cell carcinoma. Mol Oncol [print-electronic]. 2011 Oct; 5(5): 465-74. PMID: 21764651, PMCID: PMC3194764, PII: S1574-7891(11)00070-6, DOI: 10.1016/j.molonc.2011.06.002, ISSN: 1878-0261.

Oosterwijk E, Rathmell WK, Junker K, Brannon AR, Pouliot F, Finley DS, Mulders PF, Kirkali Z, Uemura H, Belldegrun A. Basic research in kidney cancer. Eur. Urol [print-electronic]. 2011 Oct; 60(4): 622-33. PMID: 21741760, PII: S0302-2838(11)00721-4, DOI: 10.1016/j.eururo.2011.06.048, ISSN: 1873-7560.

Rasmussen N, Rathmell WK. Looking beyond inhibition of VEGF/mTOR: emerging targets for renal cell carcinoma drug development. Curr Clin Pharmacol. 2011 Aug; 6(3): 199-206. PMID: 21470103, PII: BSP/CCP/E-Pub/0035, ISSN: 2212-3938.

Kurpad R, Kim W, Rathmell WK, Godley P, Whang Y, Fielding J, Smith L, Pettiford A, Schultz H, Nielsen M, Wallen EM, Pruthi RS. A multidisciplinary approach to the management of urologic malignancies: does it influence diagnostic and treatment decisions?. Urol. Oncol [print-electronic]. 2011 Jul; 29(4): 378-82. PMID: 19576797, PII: S1078-1439(09)00134-3, DOI: 10.1016/j.urolonc.2009.04.008, ISSN: 1873-2496.

Pruthi RS, Nielsen M, Heathcote S, Wallen EM, Rathmell WK, Godley P, Whang Y, Fielding J, Schultz H, Grigson G, Smith A, Kim W. A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results. BJU Int [print-electronic]. 2010 Aug; 106(3): 349-54. PMID: 20089114, PII: BJU9101, DOI: 10.1111/j.1464-410X.2009.09101.x, ISSN: 1464-410X.

Hacker KE, Rathmell WK. Emerging molecular classification in renal cell carcinoma: implications for drug development. Target Oncol [print-electronic]. 2010 Jun; 5(2): 75-84. PMID: 20645016, PMCID: PMC3392717, DOI: 10.1007/s11523-010-0144-7, ISSN: 1776-260X.

Rathmell WK, Godley PA. Recent updates in renal cell carcinoma. Curr Opin Oncol. 2010 May; 22(3): 250-6. PMID: 20154618, PMCID: PMC2906148, DOI: 10.1097/CCO.0b013e328337a5d2, ISSN: 1531-703X.

Brannon AR, Rathmell WK. Renal cell carcinoma: where will the state-of-the-art lead us?. Curr Oncol Rep. 2010 May; 12(3): 193-201. PMID: 20425079, PMCID: PMC2906141, DOI: 10.1007/s11912-010-0093-4, ISSN: 1534-6269.

Cowey CL, Fielding JR, Rathmell WK. The loss of radiographic enhancement in primary renal cell carcinoma tumors following multitargeted receptor tyrosine kinase therapy is an additional indicator of response. Urology [print-electronic]. 2010 May; 75(5): 1108-13.e1. PMID: 19931124, PII: S0090-4295(09)02392-9, DOI: 10.1016/j.urology.2009.06.105, ISSN: 1527-9995.

Wright TM, Rathmell WK. Identification of Ror2 as a hypoxia-inducible factor target in von Hippel-Lindau-associated renal cell carcinoma. J. Biol. Chem [print-electronic]. 2010 Apr 4/23/2010; 285(17): 12916-24. PMID: 20185829, PMCID: PMC2857057, PII: M109.073924, DOI: 10.1074/jbc.M109.073924, ISSN: 1083-351X.

Cowey CL, Amin C, Pruthi RS, Wallen EM, Nielsen ME, Grigson G, Watkins C, Nance KV, Crane J, Jalkut M, Moore DT, Kim WY, Godley PA, Whang YE, Fielding JR, Rathmell WK. Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J. Clin. Oncol [print-electronic]. 2010 Mar 3/20/2010; 28(9): 1502-7. PMID: 20159822, PMCID: PMC4525128, PII: JCO.2009.24.7759, DOI: 10.1200/JCO.2009.24.7759, ISSN: 1527-7755.

Chen S, Sanford CA, Sun J, Choi V, Van Dyke T, Samulski RJ, Rathmell WK. VHL and PTEN loss coordinate to promote mouse liver vascular lesions. Angiogenesis [print-electronic]. 2010 Mar; 13(1): 59-69. PMID: 20221685, PMCID: PMC2872996, DOI: 10.1007/s10456-010-9164-2, ISSN: 1573-7209.

Brannon AR, Reddy A, Seiler M, Arreola A, Moore DT, Pruthi RS, Wallen EM, Nielsen ME, Liu H, Nathanson KL, Ljungberg B, Zhao H, Brooks JD, Ganesan S, Bhanot G, Rathmell WK. Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns. Genes Cancer. 2010 Feb 2/1/2010; 1(2): 152-63. PMID: 20871783, PMCID: PMC2943630, DOI: 10.1177/1947601909359929, ISSN: 1947-6019.

Rathmell WK, Pruthi R, Wallen E. Neoadjuvant treatment of renal cell carcinoma. Urol. Oncol. 2010 Jan; 28(1): 69-73. PMID: 20123351, PII: S1078-1439(09)00037-4, DOI: 10.1016/j.urolonc.2009.02.001, ISSN: 1873-2496.

Liu H, Brannon AR, Reddy AR, Alexe G, Seiler MW, Arreola A, Oza JH, Yao M, Juan D, Liou LS, Ganesan S, Levine AJ, Rathmell WK, Bhanot GV. Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell Renal Cell Carcinoma. BMC Syst Biol. 2010; 4: 51. PMID: 20420713, PMCID: PMC2876063, PII: 1752-0509-4-51, DOI: 10.1186/1752-0509-4-51, ISSN: 1752-0509.

Benders AA, Tang W, Middeldorp JM, Greijer AE, Thorne LB, Funkhouser WK, Rathmell WK, Gulley ML. Epstein-Barr virus latent membrane protein 1 is not associated with vessel density nor with hypoxia inducible factor 1 alpha expression in nasopharyngeal carcinoma tissue. Head Neck Pathol [print-electronic]. 2009 Dec; 3(4): 276-82. PMID: 20596845, PMCID: PMC2811562, DOI: 10.1007/s12105-009-0148-8, ISSN: 1936-0568.

Wright TM, Brannon AR, Gordan JD, Mikels AJ, Mitchell C, Chen S, Espinosa I, van de Rijn M, Pruthi R, Wallen E, Edwards L, Nusse R, Rathmell WK. Ror2, a developmentally regulated kinase, promotes tumor growth potential in renal cell carcinoma. Oncogene [print-electronic]. 2009 Jul 7/9/2009; 28(27): 2513-23. PMID: 19448672, PMCID: PMC2771692, PII: onc2009116, DOI: 10.1038/onc.2009.116, ISSN: 1476-5594.

Lee CM, Hickey MM, Sanford CA, McGuire CG, Cowey CL, Simon MC, Rathmell WK. VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo. Oncogene [print-electronic]. 2009 Apr 4/9/2009; 28(14): 1694-705. PMID: 19252526, PMCID: PMC2667565, PII: onc200912, DOI: 10.1038/onc.2009.12, ISSN: 1476-5594.

Cowey CL, Rathmell WK. VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy. Curr Oncol Rep. 2009 Mar; 11(2): 94-101. PMID: 19216840, PMCID: PMC2873025, ISSN: 1534-6269.

Gordan JD, Lal P, Dondeti VR, Letrero R, Parekh KN, Oquendo CE, Greenberg RA, Flaherty KT, Rathmell WK, Keith B, Simon MC, Nathanson KL. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell. 2008 Dec 12/9/2008; 14(6): 435-46. PMID: 19061835, PMCID: PMC2621440, PII: S1535-6108(08)00366-8, DOI: 10.1016/j.ccr.2008.10.016, ISSN: 1878-3686.

Amin C, Wallen E, Pruthi RS, Calvo BF, Godley PA, Rathmell WK. Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy. Urology [print-electronic]. 2008 Oct; 72(4): 864-8. PMID: 18684493, PII: S0090-4295(08)00743-7, DOI: 10.1016/j.urology.2008.01.088, ISSN: 1527-9995.

Rathmell WK, Monk JP. High-dose-intensity MVAC for Advanced Renal Medullary Carcinoma: Report of Three Cases and Literature Review. Urology [print-electronic]. 2008 Sep; 72(3): 659-63. PMID: 18649931, PII: S0090-4295(08)00632-8, DOI: 10.1016/j.urology.2008.05.009, ISSN: 1527-9995.

Rini BI, Rathmell WK, Godley P. Renal cell carcinoma. Curr Opin Oncol. 2008 May; 20(3): 300-6. PMID: 18391630, PII: 00001622-200805000-00011, DOI: 10.1097/CCO.0b013e3282f9782b, ISSN: 1531-703X.

Cowey CL, Rathmell WK. Using Molecular Biology to Develop Drugs for Renal Cell Carcinoma. Expert Opin Drug Discov. 2008 Mar; 3(3): 311-27. PMID: 20648240, PMCID: PMC2906134, DOI: 10.1517/17460441.3.3.311, ISSN: 1746-045X.

Rathmell WK, Chen S. VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment. Expert Rev Anticancer Ther. 2008 Jan; 8(1): 63-73. PMID: 18095884, PMCID: PMC2873028, DOI: 10.1586/14737140.8.1.63, ISSN: 1744-8328.

Hacker KE, Lee CM, Rathmell WK. VHL type 2B mutations retain VBC complex form and function. PLoS ONE [print-electronic]. 2008; 3(11): e3801. PMID: 19030229, PMCID: PMC2583047, DOI: 10.1371/journal.pone.0003801, ISSN: 1932-6203.

Hickey MM, Lam JC, Bezman NA, Rathmell WK, Simon MC. Von Hippel-Lindau mutation in mice recapitulates Chuvash polycythemia via hypoxia-inducible factor-2alpha signaling and splenic erythropoiesis. J. Clin. Invest. 2007 Dec; 117(12): 3879-89. PMID: 17992257, PMCID: PMC2066197, DOI: 10.1172/JCI32614, ISSN: 0021-9738.

Gollob JA, Rathmell WK, Richmond TM, Marino CB, Miller EK, Grigson G, Watkins C, Gu L, Peterson BL, Wright JJ. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J. Clin. Oncol. 2007 Aug 8/1/2007; 25(22): 3288-95. PMID: 17664476, PII: 25/22/3288, DOI: 10.1200/JCO.2007.10.8613, ISSN: 1527-7755.

Rathmell WK, Martz CA, Rini BI. Renal cell carcinoma. Curr Opin Oncol. 2007 May; 19(3): 234-40. PMID: 17414642, PII: 00001622-200705000-00011, DOI: 10.1097/CCO.0b013e3280ad4388, ISSN: 1040-8746.

Rini BI, Rathmell WK. Biological aspects and binding strategies of vascular endothelial growth factor in renal cell carcinoma. Clin. Cancer Res. 2007 Jan 1/15/2007; 13(2 Pt 2): 741s-746s. PMID: 17255303, PII: 13/2/741s, DOI: 10.1158/1078-0432.CCR-06-2110, ISSN: 1078-0432.

Rini BI, Campbell SC, Rathmell WK. Renal cell carcinoma. Curr Opin Oncol. 2006 May; 18(3): 289-96. PMID: 16552243, PII: 00001622-200605000-00013, DOI: 10.1097/01.cco.0000219260.60714.c4, ISSN: 1531-703X.

Rathmell WK, Wright TM, Rini BI. Molecularly targeted therapy in renal cell carcinoma. Expert Rev Anticancer Ther. 2005 Dec; 5(6): 1031-40. PMID: 16336094, DOI: 10.1586/14737140.5.6.1031, ISSN: 1744-8328.

Rathmell WK, Simon MC. VHL: oxygen sensing and vasculogenesis. J. Thromb. Haemost [print-electronic]. 2005 Dec; 3(12): 2627-32. PMID: 15975138, PII: JTH1441, DOI: 10.1111/j.1538-7836.2005.01441.x, ISSN: 1538-7933.

Rathmell WK, Godley PA, Rini BI. Renal cell carcinoma. Curr Opin Oncol. 2005 May; 17(3): 261-7. PMID: 15818172, PII: 00001622-200505000-00012, ISSN: 1040-8746.

Rathmell WK, Hickey MM, Bezman NA, Chmielecki CA, Carraway NC, Simon MC. In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations. Cancer Res. 2004 Dec 12/1/2004; 64(23): 8595-603. PMID: 15574766, PII: 64/23/8595, DOI: 10.1158/0008-5472.CAN-04-1430, ISSN: 0008-5472.

Rathmell WK, Godley PA. Renal cell carcinoma. Curr Opin Oncol. 2004 May; 16(3): 247-52. PMID: 15069321, PII: 00001622-200405000-00010, ISSN: 1040-8746.

Rathmell WK, Malkowicz SB, Holroyde C, Luginbuhl W, Vaughn DJ. Phase II trial of 5-fluorouracil and leucovorin in combination with interferon-alpha and interleukin-2 for advanced renal cell cancer. Am. J. Clin. Oncol. 2004 Apr; 27(2): 109-12. PMID: 15057147, PII: 00000421-200404000-00001, ISSN: 1537-453X.

Rathmell WK, Acs G, Simon MC, Vaughn DJ. HIF transcription factor expression and induction of hypoxic response genes in a retroperitoneal angiosarcoma. Anticancer Res. 2004 Jan; 24(1): 167-9. PMID: 15015593, ISSN: 0250-7005.

Mack FA, Rathmell WK, Arsham AM, Gnarra J, Keith B, Simon MC. Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth. Cancer Cell. 2003 Jan; 3(1): 75-88. PMID: 12559177, PMCID: PMC4120823, PII: S1535610802002404, ISSN: 1535-6108.

Rathmell WK, Arguin P, Chan S, Yu A. Yersinia pseudotuberculosis bacteremia and splenic abscess in a patient with non-insulin-dependent diabetes mellitus. West. J. Med. 1999 Feb; 170(2): 110-2. PMID: 10063398, PMCID: PMC1305451, ISSN: 0093-0415.

Smider V, Rathmell WK, Brown G, Lewis S, Chu G. Failure of hairpin-ended and nicked DNA To activate DNA-dependent protein kinase: implications for V(D)J recombination. Mol. Cell. Biol. 1998 Nov; 18(11): 6853-8. PMID: 9774698, PMCID: PMC109268, ISSN: 0270-7306.

Rathmell WK, Kaufmann WK, Hurt JC, Byrd LL, Chu G. DNA-dependent protein kinase is not required for accumulation of p53 or cell cycle arrest after DNA damage. Cancer Res. 1997 Jan 1/1/1997; 57(1): 68-74. PMID: 8988043, ISSN: 0008-5472.

Errami A, Smider V, Rathmell WK, He DM, Hendrickson EA, Zdzienicka MZ, Chu G. Ku86 defines the genetic defect and restores X-ray resistance and V(D)J recombination to complementation group 5 hamster cell mutants. Mol. Cell. Biol. 1996 Apr; 16(4): 1519-26. PMID: 8657125, PMCID: PMC231136, ISSN: 0270-7306.

Smider V, Rathmell WK, Lieber MR, Chu G. Restoration of X-ray resistance and V(D)J recombination in mutant cells by Ku cDNA. Science. 1994 Oct 10/14/1994; 266(5183): 288-91. PMID: 7939667, ISSN: 0036-8075.

Rathmell WK, Chu G. Involvement of the Ku autoantigen in the cellular response to DNA double-strand breaks. Proc. Natl. Acad. Sci. U.S.A. 1994 Aug 8/2/1994; 91(16): 7623-7. PMID: 8052631, PMCID: PMC44454, ISSN: 0027-8424.

Rathmell WK, Chu G. A DNA end-binding factor involved in double-strand break repair and V(D)J recombination. Mol. Cell. Biol. 1994 Jul; 14(7): 4741-8. PMID: 7516471, PMCID: PMC358847, ISSN: 0270-7306.

Wiens DJ, Mann TK, Fedderson DE, Rathmell WK, Franck BH. Early heart development in the chick embryo: effects of isotretinoin on cell proliferation, alpha-actin synthesis, and development of contractions. Differentiation. 1992 Oct; 51(2): 105-12. PMID: 1473624, ISSN: 0301-4681.